Enhanced Antitumor Immunity Through T Cell Activation with Optimized Tandem Double-OX40L mRNAs
In conclusion, our findings highlight the therapeutic potential of the optimized diOX40L mRNA cancer agent in cancer treatment and its potential as an innovative alternative to protein-based therapies. The study underscores the significance of mRNA-based agents in modulating the immune microenvironment and enhancing antitumor responses.
Authors
- Zhaohai Wang (ORCID: https://orcid.org/0000-0002-2703-8602)
- Yuying Tian
- Minggen Hu (ORCID: https://orcid.org/0000-0001-7933-7850)
- Zherui Liu (ORCID: https://orcid.org/0000-0002-1991-3999)
- Zhuoya Deng
- Rong Liu (ORCID: https://orcid.org/0000-0001-5170-6474)
- Penghui Yang
- Zhaohui Xiao
- Yongru Xu
- Jing Wang (ORCID: https://orcid.org/0000-0001-7431-8925)
Institutions
- Capital Medical University (CN)
- Peking University (CN)
- Chinese PLA General Hospital (CN)
- Peking University People's Hospital (CN)
- Beijing YouAn Hospital (CN)
Publication Details
- Journal
- International Journal of Nanomedicine
- Published
- 2025-03-01
- DOI
- https://doi.org/10.2147/ijn.s479434
- Citations
- 4
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 4.18